Mainz Biomed B.V. (MYNZ)
NASDAQ: MYNZ · IEX Real-Time Price · USD
0.680
+0.034 (5.25%)
At close: May 17, 2024, 3:50 PM
0.675
-0.005 (-0.72%)
After-hours: May 17, 2024, 4:42 PM EDT
Mainz Biomed B.V. Revenue
In the year 2023, Mainz Biomed B.V. had annual revenue of $895.48K with 69.00% growth. Revenue in the quarter ending December 31, 2023 was $214.76K with 11.11% year-over-year growth.
Revenue (ttm)
$895.48K
Revenue Growth
+69.00%
P/S Ratio
16.62
Revenue / Employee
$13,777
Employees
65
Market Cap
14.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Star Equity Holdings | 45.79M |
Pieris Pharmaceuticals | 40.93M |
NEXGEL | 4.74M |
Immuron | 2.43M |
Addex Therapeutics | 1.96M |
Organovo Holdings | 242.00K |
MYNZ News
- 11 days ago - Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. - GlobeNewsWire
- 23 days ago - Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic - GlobeNewsWire
- 5 weeks ago - Mainz Biomed Reports Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment - GlobeNewsWire
- 2 months ago - Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options - GlobeNewsWire
- 2 months ago - Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations - GlobeNewsWire
- 2 months ago - Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic - GlobeNewsWire
- 2 months ago - Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community - GlobeNewsWire